Interleukin-6 infusion blunts proinflammatory cytokine production without causing systematic toxicity in a swine model of uncontrolled hemorrhagic shock

Journal of Trauma - Injury, Infection and Critical Care

Volumn 57, Issue 5, 2004, Pages 970-978

  Brundage, Susan I ^a,d   Zautke, N A ^a   Holcomb, J B ^b   Spain, D A ^a   Lam, J C ^a   Mastrangelo, M A ^c   Macaitis, J M ^b   Tweardy, D J ^c   Patton Jr , Joe H ^d   West, Michael A ^d  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6; MESSENGER RNA; PLACEBO; RECOMBINANT INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATOCRIT; HEMODILUTION; HEMORRHAGIC SHOCK; LEUKOCYTE COUNT; LIVER INJURY; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; RESUSCITATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SPLENECTOMY; SWINE; THROMBOCYTE COUNT;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRANULOCYTE COLONY-STIMULATING FACTOR; INFLAMMATION; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; LUNG; PLACEBOS; RANDOM ALLOCATION; RECOMBINANT PROTEINS; REPERFUSION INJURY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SHOCK, HEMORRHAGIC; SWINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 9644291410     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TA.0000141970.68269.AC     Document Type: Article

References (42)

1. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med. 1993;119:771-778.
2. Meduri GU, Headley S, Kohler G, et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest. 1995;107:1062-1073.
3. Amalich F, Garcia-Palomero E, Lopez J, et al. Predictive value of nuclear factor kappaB activity and plasma cytokine levels in patients with sepsis. Infect Immun. 2000;68:1942-1945.
4. Meng ZH, Dyer K, Billiar TR, Tweardy DJ. Distinct effects of systemic infusion of G-CSF vs. IL-6 on lung and liver inflammation and injury in hemorrhagic shock. Shock. 2000;14:41-48.
5. Moore EE, Cogbill TH, Jurkovich GJ, Shackford SR, Malangoni MA, Champion HR. Organ injury scaling: spleen and liver (1994 revision). J Trauma. 1995;38:323-324.
6. Holcomb JB, Pusateri AE, Harris RA, et al. Dry fibrin sealant dressings reduce blood loss, resuscitation volume, and improve survival in hypothermic coagulopathic swine with grade V liver injuries. J Trauma. 1999;47:233-240, discussion 240-232.
7. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
8. Gloster SE, Strom AD. Sus scrofa granulocyte-colony stimulating factor mRNA, complete cds. Direct Submission, NCBI, NIH, NIH. 1996.
9. Choi CS, Lin GF, Molitor TW, Murtaugh MP. Complete nucleotide sequence of a cDNA encoding porcine tumor necrosis factor-alpha. Anim Biotechnol. 1991;2:97-105.
10. Mathialagan N, Bixby JA, Roberts RM. Expression of interleukin-6 in porcine, ovine, and bovine preimplantation conceptuses. Mol Reprod Dev. 1992;32:324-330.
11. Moore FA, Sauaia A, Moore EE, Haenel JB, Burch JM, Lezotte DC. Postinjury multiple organ failure: a bimodal phenomenon. J Trauma. 1996;40:501-510, discussion 510-502.
12. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA. Six at six: interleukin-6 measured 6 hours after the initiation of sepsis predicts mortality over 3 days. Shock. 2002;17:463-467.
13. Kopf M, Baumann H, Freer G, et al. Impaired immune and acutephase responses in interleukin-6-deficient mice. Nature. 1994;368:339-342.
14. Fattori E, Cappelletti M, Costa P, et al. Defective inflammatory response in interleukin-6-deficient mice. J Exp Med. 1994;180:1243-1250.
15. Dalrymple SA, Slattery R, Aud DM, Krishna M, Lucian LA, Murray R. Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection. Infect Immun. 1996;64:3231-3235.
16. Meng ZH, Dyer K, Billiar TR, Tweardy DJ. Essential role for IL-6 in postresuscitation inflammation in hemorrhagic shock. Am J Physiol Cell Physiol. 2001;280:C343-C351.
17. Romano M, Sironi M, Toniatti C, et al, Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 1997;6:315-325.
18. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998;334(Pt 2):297-314.
19. Barton BE. IL-6: insights into novel biological activities. Clin Immunol Immunopathol. 1997;85:16-20.
20. Barton BE, Jackson JV. Protective role of interleukin-6 in the lipopolysaccharide-galactosamine septic shock model. Infect Immun. 1993;61:1496-1499.
21. Barton BE, Shortall J, Jackson JV. Interleukins 6 and 11 protect mice from mortality in a staphylococcal enterotoxin-induced toxic shock model. Infect Immun. 1996;64(3):714-718.
22. Camargo CA, Jr., Madden JF, Gao W, Selvan RS, Clavien PA. Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology. 1997;26(6):1513-1520.
23. Ulich TR, Yin S, Guo K, Yi ES, Remick D, del Castillo J. Intratracheal injection of endotoxin and cytokines. II. Interleukin-6 and transforming growth factor beta inhibit acute inflammation. Am J Pathol. May 1991;138(5):1097-1101.
24. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. Jan 1 1994;83(1):113-118.
25. Ernst TJ, Ritchie AR, Demetri GD, Griffin JD. Regulation of granulocyte- and monocyte-colony stimulating factor mRNA levels in human blood monocytes is mediated primarily at a posttranscriptional level. Journal of Biological Chemistry. 1989;264:5700-5710.
26. Oster W, Lindemann A, Mertelsmann R, Hermann F. Granulocyte-macrophage colony-stimulating factor (CSF) and multilineage CSF recruit human monocytes to express granulocyte CSF. Blood. 1989;73:64-70.
27. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood. 1991;78:2791-2808.
28. Tkatch LS, Tweardy DJ. Human granulocyte colony-stimulating factor (G-CSF), the premier granulopoietin: biology, clinical utility, and receptor structure and function. Lymphokine & Cytokine Research. 1993;12(6):477-488.
29. Tweardy DJ, Mott PL, Glazer EW. Monokine modulation of human astroglial cell production of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. I. Effects of IL-1 alpha and IL-beta. Journal of Immunology. 1990;144(6):2233-2241.
30. Tweardy DJ, Glazer EW, Mott PL, Anderson K. Modulation by tumor necrosis factor-alpha of human astroglial cell production of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF). Journal of Neuroimmunology. 1991;32(3):269-278.
31. Kerst JM, de HM, van dSCE, et al. Recombinant granulocyte colony-stimulating factor administration to healthy volunteers: induction of immunophenotypically and functionally altered neutrophils via an effect on myeloid progenitor cells. Blood. 1993;82(11):3265-3272.
32. Yuo A, Kitagawa S, Ohsaka A, et al. Recombinant human granulocyte colony-stimulating factor as an activator of human granulocytes: potentiation of responses triggered by receptor-mediated agonists and stimulation of C3bi receptor expression and adherence. Blood. 1989;74(6):2144-2149.
33. Wang JM, Chen ZG, Colella S, et al. Chemotactic activity of recombinant human granulocyte colony-stimulating factor. Blood. 1988;72(5):1456-1460.
34. Smith WB, Gamble JR, Vadas MA. The role of granulocyte-macrophage and granulocyte colony-stimulating factors in neutrophil transendothelial migration: comparison with interleukin-8. Experimental Hematology. 1994;22(3):329-334.
35. Kitagawa S, Yuo A, Souza LM, Saito M, Miura Y, Takaku F. Recombinant human granulocyte colony-stimulating factor enhances superoxide release in human granulocytes stimulated by the chemotactic peptide. Biochemical & Biophysical Research Communications. 1987;144(3):1143-1146.
36. Yuo A, Kitagawa S, Ohsaka A, Saito M, Takaku F. Stimulation and priming of human neutrophils by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: qualitative and quantitative differences. Biochemical & Biophysical Research Communications. 1990;171(1):491-497.
37. Nathan CF. Respiratory burst in adherent human neutrophils: triggering by colony-stimulating factors CSF-GM and CSF-G. Blood. 1989;73(1):301-306.
38. Adachi S, Kubota M, Wakazono Y, et al. Mechanism of enhancement of neutrophil survival by granulocyte colony-stimulating factor and adenine. Experimental Hematology. 1993;21(9):1213-1218.
39. Patton JH, Jr., Lyden SP, Ragsdale DN, Croce MA, Fabian TC, Proctor KG. Granulocyte colony-stimulating factor improves host defense to resuscitated shock and polymicrobial sepsis without provoking generalized neutrophil-mediated damage. J Trauma. May 1998;44(5):750-758; discussion 758-759.
40. Davis KA, Fabian TC, Ragsdale DN, Trenthem LL, Croce MA, Proctor KG. Granulocyte colony-stimulating factor and neutrophil-related changes in local host defense during recovery from shock and intra-abdominal sepsis. Surgery. Aug. 1999;126(2):305-313.
41. Quezado ZM, Eichacker P. Q. Prophylactic granulocyte colony-stimulating factor in the critically ill: carefully balancing the benefits and risks. Crit Care Med. Sep. 2002;30(9):2162-2164.
42. Biffl WL, Moore EE, Moore FA, Peterson VM. Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation? Ann Surg. Nov. 1996;224(5):647-664.